A decentralized clinical trial (DCT) moves some or all trial activities away from a central site. It uses telehealth visits, local labs, and direct-to-patient drug shipment so participants can take part from home. Sponsors have expanded the use of these elements steadily since the FDA finalized dedicated guidance on the model. How much of the industry has adopted them varies by therapeutic area and by which source is tracking it. This guide covers what qualifies as decentralized, how hybrid and fully remote models differ, where adoption stands today, and the one recruitment shift sponsors need to plan for: geography stops being the limiting factor.
What Is A Decentralized Clinical Trial?
The FDA defines a decentralized clinical trial as one where some or all trial-related activities happen at locations other than the traditional investigator site. Those activities rely on tools like telemedicine, electronic informed consent, and local or mobile healthcare providers.
That definition comes directly from the agency's guidance on conducting clinical trials with decentralized elements, which frames decentralization as a spectrum rather than an all-or-nothing switch. A trial can decentralize one procedure, several, or nearly all of them, and it still runs under the same regulatory framework as a fully site-based study.
The Core Components Of A Decentralized Trial
Each component below substitutes for something a participant would otherwise drive to a site to do.
Telemedicine visits replace in-person check-ins for procedures that do not require hands-on equipment. A study coordinator or investigator can review symptoms, adjust a protocol question, or check adherence over video. Electronic patient-reported outcomes and electronic clinical outcome assessments, known as ePRO and eCOA, let participants log symptoms, side effects, and questionnaire responses from a phone or tablet. This replaces the paper forms participants would otherwise fill out during a site visit.
Mobile nursing and local labs bring a phlebotomist or a nearby clinic into the loop for blood draws, vitals, and other procedures that need a trained professional but not the trial's own facility. Direct-to-patient drug shipment sends the investigational product to the participant's home instead of dispensing it at the site.
Hybrid Vs. Fully Decentralized Trials
Most DCTs today are hybrid, combining a small number of in-person visits with remote monitoring. Fully remote models still struggle with procedures that require in-person equipment or biospecimen collection. A hybrid design keeps a screening visit, a baseline scan, or an infusion at a site while moving routine follow-ups, symptom tracking, and drug delivery off-site. A fully decentralized trial removes the site almost entirely. This works best for conditions where every assessment can happen through a device, a home health visit, or a shipped kit.
The choice between the two comes down to what the protocol actually requires. Imaging, biopsies, and infusions still need a site's equipment and staff. Symptom tracking, medication adherence, and simple vitals do not. Sponsors that try to force a fully remote design onto a protocol with hands-on procedures usually end up bolting site visits back on mid-study. That costs more than planning for a hybrid model from the start.
Why Adoption Is Growing (And Where It Stands Today)
Sponsors are adopting decentralized elements primarily to cut patient dropout and speed enrollment, not to replace site-based trials outright: most current studies remain hybrid rather than fully remote. Reducing the number of required site visits lowers the travel burden that causes many participants to drop out partway through a study. It also opens enrollment to people who live far from a major medical center. ePRO and eCOA also capture data faster and more completely, giving sponsors a cleaner adherence picture than paper diaries filled out between visits.
The table below compares traditional, hybrid, and fully decentralized designs across the dimensions that matter most to a sponsor planning a protocol.
Decentralizing a trial also introduces new operational and data-handling work, from validating remote devices to keeping a consistent chain of custody on shipped drugs and collected samples. That work needs its own planning, separate from the recruitment question this guide focuses on. For CROs managing that operational shift across multiple sponsor protocols, see how CRO marketing services adapt to decentralized study designs.
How Decentralized Trial Recruitment Is Different
Because a decentralized trial isn't tied to driving distance from a single site, recruitment can run as a national, geo-targeted paid media campaign instead of a local-radius push around each investigator location. That shift changes who runs it and how it's measured.
Site-based recruitment has always worked as a radius problem. A study team maps the drive time around each investigator location, runs local outreach, maybe some print or radio, and waits for people within that radius to hear about the trial and qualify. That model breaks down once participation doesn't require travel. A participant in a decentralized trial can complete an ePRO check-in from anywhere the protocol allows. As a result, recruiting only within an hour of a physical site leaves most of the eligible population untouched.
That reality moves the channel mix toward paid social and paid search with targeting built around eligibility criteria and geography at a national or regional scale, not a site radius. It also shifts the audience and messaging judgment from a site coordinator managing local outreach to a media buyer who can build and adjust a nationwide funnel.
Measurement changes with it. A site-based study tracks enrollment per site and compares locations against each other. A decentralized study needs a single measure that works across the whole geography it draws from: cost per qualified lead across a national pool. That figure is tracked against a screening funnel built for volume rather than a handful of site coordinators fielding phone calls.
Brighter Click treats this as its core clinical-trials focus: geo-targeted paid media for patient recruitment, reviewed against IRB ad-approval and FTC advertising standards, for CROs and healthtech brands, not UGC production.
Its own clinical-trials case study shows the model at work. Working with Adams Clinical, spend scaled from $360,000 to $600,000 a month, with cost per lead down 45.9% with geo-targeting and click-to-conversion improving 91.5%. Final cost-per-lead landed between $20 and $39. Those numbers are evidence that a properly targeted national campaign can perform at the scale a decentralized trial's recruitment pool requires. They are not a claim that any single result transfers directly to another protocol.
Not every clinical-trial recruitment vendor has adjusted its pricing and staffing model to a national, decentralized reach. Sponsors weighing that fit can compare vetted clinical trial recruitment companies before choosing a partner.
Turning the reframe into a live campaign means selecting channels, designing screening funnels, and testing creative at national scale. That next layer is covered in the full clinical-trial recruitment marketing playbook.
Ready To Plan Recruitment For A Decentralized Trial?
A decentralized design changes who should run recruitment and how success gets measured, and getting that wrong costs weeks of enrollment time no protocol has to spare. Brighter Click's clinical-trials team builds and manages the geo-targeted paid media campaigns behind that shift, reviewed against IRB ad-approval and FTC advertising standards from creative through targeting. Explore healthcare marketing support for recruitment, or book a call below to talk through a specific protocol.
Frequently Asked Questions
What Is The Difference Between Centralized And Decentralized Clinical Trials?
In a centralized clinical trial, participants travel to a single investigator site for every study visit. In a decentralized clinical trial, some or all trial activities happen away from that site through telehealth visits, local labs, mobile nurses, and drug shipments to the participant's home. Most modern studies sit between the two, running a hybrid mix of in-person and remote elements.
What Is A Hybrid Decentralized Clinical Trial?
A hybrid decentralized trial combines in-person visits at a traditional site with remote elements such as telehealth check-ins, electronic consent, and home drug delivery. Most decentralized trials today run as hybrids, because procedures like imaging or biospecimen collection still require on-site equipment and staff.
Are Decentralized Clinical Trials Cheaper Than Traditional Trials?
Not automatically. Decentralized trials can lower costs through faster recruitment, higher retention, and a smaller site footprint, but they add upfront spending on technology platforms, device validation, and remote logistics. Published NIH reviews describe the savings as possible rather than guaranteed, and the balance depends on trial design and phase.
Does The FDA Allow Decentralized Clinical Trials?
Yes. The FDA published guidance titled Conducting Clinical Trials with Decentralized Elements, finalized in September 2024, covering trial design, remote data collection, the role of local healthcare providers, and sponsor oversight. Decentralized trials follow the same regulatory standards as site-based trials. What changes is where trial activities happen, not the rules that govern them.
How Does Direct-To-Patient Drug Shipment Work In A Decentralized Trial?
Direct-to-patient shipment sends the investigational drug from the sponsor or a central pharmacy straight to the participant's home instead of dispensing it at a site. It suits drugs with stable storage profiles and requires temperature tracking, chain-of-custody documentation, and adherence monitoring. Drugs that need infusion or close clinical supervision are still administered in person.
What Are The Four Types Of Clinical Trials?
Interventional studies are commonly grouped into four phases. Phase 1 tests safety in a small group, Phase 2 measures effectiveness and side effects, Phase 3 compares the treatment against current standards in large populations, and Phase 4 monitors long-term safety after approval. Decentralized elements can appear in any phase.
How Does Patient Recruitment Change In A Decentralized Clinical Trial?
Recruitment stops being limited to people within driving distance of a trial site. Because a decentralized trial can enroll from an entire country, outreach shifts from local site-radius campaigns to national geo-targeted paid media with screening funnels built for volume. Measurement shifts with it, from per-site enrollment counts to cost per qualified lead across a national pool.
